Patients were randomly assigned to receive either arm A ( OSI-211 1.8 mg/m ( 2 ) / d administered by 30-minute intravenous infusion on days 1 , 2 , and 3 every 3 weeks ) or arm B ( OSI-211 2.4 mg/m ( 2 ) / d administered by 30-minute intravenous infusion on days 1 and 8 every 3 weeks ) .
